These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30358069)

  • 1. Clinically relevant differences between assays for von Willebrand factor activity.
    Boender J; Eikenboom J; van der Bom JG; Meijer K; de Meris J; Fijnvandraat K; Cnossen MH; Laros-van Gorkom BAP; van Heerde WL; Mauser-Bunschoten EP; de Maat MPM; Leebeek FWG;
    J Thromb Haemost; 2018 Dec; 16(12):2413-2424. PubMed ID: 30358069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
    Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
    J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers.
    Szederjesi A; Baronciani L; Budde U; Castaman G; Colpani P; Lawrie AS; Liu Y; Montgomery R; Peyvandi F; Schneppenheim R; Patzke J; Bodó I
    J Thromb Haemost; 2020 Oct; 18(10):2513-2523. PubMed ID: 32573891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
    Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb).
    Patzke J; Favaloro EJ
    Methods Mol Biol; 2017; 1646():453-460. PubMed ID: 28804847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
    Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
    Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
    Favaloro EJ
    Methods Mol Biol; 2017; 1646():391-402. PubMed ID: 28804843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease.
    Stufano F; Baronciani L; Bucciarelli P; Boscarino M; Colpani P; Pagliari MT; Peyvandi F
    Haemophilia; 2020 Mar; 26(2):298-305. PubMed ID: 32107842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
    Hayward CP; Moffat KA; Graf L
    Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory Testing for von Willebrand Factor Activity by a Glycoprotein Ib-Binding Assay (VWF:GPIbR): HemosIL von Willebrand Factor Ristocetin Cofactor Activity on ACL TOP
    Seidizadeh O; Peyvandi F
    Methods Mol Biol; 2023; 2663():669-677. PubMed ID: 37204744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New advances in the diagnosis of von Willebrand disease.
    Sharma R; Haberichter SL
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):596-600. PubMed ID: 31808831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study.
    Favaloro EJ; Bonar R; Hollestelle MJ; Jennings I; Mohammed S; Meijer P; Woods T; Meiring M
    Thromb Res; 2018 Jun; 166():96-105. PubMed ID: 29727738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays.
    Colpani P; Baronciani L; Stufano F; Cozzi G; Boscarino M; Pagliari MT; Biguzzi E; Peyvandi F
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100139. PubMed ID: 37215093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies.
    Favaloro EJ; Oliver S; Mohammed S; Vong R
    Haemophilia; 2020 May; 26(3):503-512. PubMed ID: 32159272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.